Spots Global Cancer Trial Database for non small cell lung cancer stage iiib
Every month we try and update this database with for non small cell lung cancer stage iiib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | NCT03302247 | Non Small Cell ... | Nivolumab Nivolumab+Gemci... | 18 Years - | Fox Chase Cancer Center | |
| A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer | NCT03472053 | Non Small Cell ... | BIO-11006 plus ... Standard of Car... | 18 Years - 70 Years | BioMarck Pharmaceuticals, Ltd. | |
| Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer | NCT03396185 | EGFR Gene Mutat... Non Small Cell ... Non Small Cell ... | Icotinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | NCT06436144 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Osimertinib | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | NCT06436144 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Osimertinib | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients | NCT03334071 | Non Small Cell ... Non Small Cell ... Non Small Cell ... | Exercise | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | NCT04432207 | Non Small Cell ... Non Small Cell ... Non-small Cell ... Squamous Non-sm... Large Cell Carc... Adenocarcinoma ... | IMU-201 (admini... IMU-201 (admini... IMU-201 (admini... Atezolizumab Standard of car... | 18 Years - | Imugene Limited | |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients | NCT03334071 | Non Small Cell ... Non Small Cell ... Non Small Cell ... | Exercise | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | NCT03307785 | Neoplasms Metastatic Canc... Advanced Cancer Solid Tumor Non Small Cell ... Non Small Cell ... Non Small Cell ... | Niraparib TSR-042 Carboplatin-Pac... Bevacizumab TSR-022 Carboplatin-Pem... Carboplatin-Nab... | 18 Years - | Tesaro, Inc. | |
| Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) | NCT03288870 | Non Small Cell ... Non-Small Cell ... | BCD-100 Docetaxel | 18 Years - | Biocad | |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | NCT03307785 | Neoplasms Metastatic Canc... Advanced Cancer Solid Tumor Non Small Cell ... Non Small Cell ... Non Small Cell ... | Niraparib TSR-042 Carboplatin-Pac... Bevacizumab TSR-022 Carboplatin-Pem... Carboplatin-Nab... | 18 Years - | Tesaro, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
